These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2597177)

  • 41. Catechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neurons.
    Storch A; Blessing H; Bareiss M; Jankowski S; Ling ZD; Carvey P; Schwarz J
    Mol Pharmacol; 2000 Mar; 57(3):589-94. PubMed ID: 10692500
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness.
    Léger G; Gjedde A; Kuwabara H; Guttman M; Cumming P
    Synapse; 1998 Dec; 30(4):351-61. PubMed ID: 9826227
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Catechol O-methyltransferase. 10. 5-Substituted 3-hydroxy-4-methoxybenzoic acids (isovanillic acids) and 5-substituted 3-hydroxy-4-methoxybenzaldehydes (isovanillins) as potential inhibitors.
    Borchardt RT; Huber JA; Houston M
    J Med Chem; 1982 Mar; 25(3):258-63. PubMed ID: 7069704
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition.
    Sundberg S; Scheinin M; Ojala-Karlsson P; Akkila J; Gordin A
    Eur J Clin Pharmacol; 1993; 44(3):287-90. PubMed ID: 8491246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application.
    Bonifácio MJ; Archer M; Rodrigues ML; Matias PM; Learmonth DA; Carrondo MA; Soares-Da-Silva P
    Mol Pharmacol; 2002 Oct; 62(4):795-805. PubMed ID: 12237326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Competitive inhibition of catechol O-methyltransferase by RO-4-4602.
    Buu NT; Kuchel O; Parent MT
    Can J Biochem; 1977 Jul; 55(7):771-3. PubMed ID: 890572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.
    Lautala P; Ulmanen I; Taskinen J
    Mol Pharmacol; 2001 Feb; 59(2):393-402. PubMed ID: 11160877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro susceptibility of Helicobacter pylori to nitecapone.
    Rautelin H; Renkonen OV; Kosunen TV
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):274-5. PubMed ID: 1597212
    [No Abstract]   [Full Text] [Related]  

  • 49. Antioxidant properties of nitecapone (OR-462).
    Suzuki YJ; Tsuchiya M; Safadi A; Kagan VE; Packer L
    Free Radic Biol Med; 1992 Nov; 13(5):517-25. PubMed ID: 1334029
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Strong inhibitory effects of common tea catechins and bioflavonoids on the O-methylation of catechol estrogens catalyzed by human liver cytosolic catechol-O-methyltransferase.
    Nagai M; Conney AH; Zhu BT
    Drug Metab Dispos; 2004 May; 32(5):497-504. PubMed ID: 15100171
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New isoflavones, inhibiting catechol-O-methyltransferase, produced by Streptomyces.
    Chimura H; Sawa T; Kumada Y; Naganawa H; Matsuzaki M
    J Antibiot (Tokyo); 1975 Sep; 28(9):619-26. PubMed ID: 1184476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Catechol metabolites of polychlorinated biphenyls inhibit the catechol-O-methyltransferase-mediated metabolism of catechol estrogens.
    Garner CE; Burka LT; Etheridge AE; Matthews HB
    Toxicol Appl Pharmacol; 2000 Jan; 162(2):115-23. PubMed ID: 10637135
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
    Männistö PT; Tuomainen P; Tuominen RK
    Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
    [TBL] [Abstract][Full Text] [Related]  

  • 54. COMT inhibition with nitecapone does not affect the tyramine pressor response.
    Sundberg S; Gordin A
    Br J Clin Pharmacol; 1991 Jul; 32(1):130-2. PubMed ID: 1888633
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Kinetic studies on the O-methylation of dopamine by human brain membrane-bound catechol O-methyltransferase.
    Rivett AJ; Roth JA
    Biochemistry; 1982 Apr; 21(8):1740-2. PubMed ID: 7082642
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase.
    Holden JE; Doudet D; Endres CJ; Chan GL; Morrison KS; Vingerhoets FJ; Snow BJ; Pate BD; Sossi V; Buckley KR; Ruth TJ
    J Nucl Med; 1997 Oct; 38(10):1568-74. PubMed ID: 9379194
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A simple colorimetric assay for catechol-O-methyl transferase.
    Herblin WF
    Anal Biochem; 1973 Jan; 51(1):19-22. PubMed ID: 4688015
    [No Abstract]   [Full Text] [Related]  

  • 58. Rat liver catechol-O-methyltransferase kinetics and assay methodology.
    Borges N; Vieira-Coelho MA; Parada A; Soares-da-Silva P
    J Enzyme Inhib; 1998 Sep; 13(6):473-83. PubMed ID: 9825310
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Norepinephrine metabolites in plasma as indicators of pharmacological inhibition of monoamine oxidase and catechol O-methyltransferase.
    Scheinin M; Illi A; Koulu M; Ojala-Karlsson P
    Adv Pharmacol; 1998; 42():367-70. PubMed ID: 9327918
    [No Abstract]   [Full Text] [Related]  

  • 60. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.
    Vieira-Coelho MA; Gomes P; Serrão MP; Soares-da-Silva P
    Kidney Int; 2001 May; 59(5):1683-94. PubMed ID: 11318939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.